The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation
Abstract Background Refinement of parameters defining prostate cancer (PC) prognosis are urgently needed to identify patients with indolent versus aggressive disease. The Canadian Prostate Cancer Biomaker Network (CPCBN) consists of researchers from four Canadian provinces to create a validation coh...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-09-01
|
| Series: | BMC Urology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12894-018-0392-x |
| _version_ | 1819092613833162752 |
|---|---|
| author | Véronique Ouellet Armen Aprikian Alain Bergeron Fadi Brimo Robert G. Bristow Simone Chevalier Darrel Drachenberg Ladan Fazli Neil E. Fleshner Martin Gleave Pierre Karakiewicz Laurence Klotz Louis Lacombe Jean-Baptiste Lattouf Theodorus van der Kwast Jeremy A. Squire Mathieu Latour Dominique Trudel Anne-Marie Mes-Masson Fred Saad |
| author_facet | Véronique Ouellet Armen Aprikian Alain Bergeron Fadi Brimo Robert G. Bristow Simone Chevalier Darrel Drachenberg Ladan Fazli Neil E. Fleshner Martin Gleave Pierre Karakiewicz Laurence Klotz Louis Lacombe Jean-Baptiste Lattouf Theodorus van der Kwast Jeremy A. Squire Mathieu Latour Dominique Trudel Anne-Marie Mes-Masson Fred Saad |
| author_sort | Véronique Ouellet |
| collection | DOAJ |
| description | Abstract Background Refinement of parameters defining prostate cancer (PC) prognosis are urgently needed to identify patients with indolent versus aggressive disease. The Canadian Prostate Cancer Biomaker Network (CPCBN) consists of researchers from four Canadian provinces to create a validation cohort to address issues dealing with PC diagnosis and management. Methods A total of 1512 radical prostatectomy (RP) specimens from five different biorepositories affiliated with teaching hospitals were selected to constitute the cohort. Tumoral and adjacent benign tissues were arrayed on tissue microarrays (TMAs). A patient clinical database was developed and includes data on diagnosis, treatment and clinical outcome. Results Mean age at diagnosis of patients in the cohort was 61 years. Of these patients, 31% had a low grade (≤6) Gleason score (GS), 55% had GS 7 (40% of 3 + 4 and 15% of 4 + 3) and 14% had high GS (≥8) PC. The median follow-up of the cohort was 113 months. A total of 34% had a biochemical relapse, 4% developed bone metastasis and 3% of patients died from PC while 9% died of other causes. Pathological review of the TMAs confirmed the presence of tumor and benign tissue cores for > 94% of patients. Immunohistochemistry and FISH analyses, performed on a small set of specimens, showed high quality results and no biorepository-specific bias. Conclusions The CPCBN RP cohort is representative of real world PC disease observed in the Canadian population. The frequency of biochemical relapse and bone metastasis as events allows for a precise assessment of the prognostic value of biomarkers. This resource is available, in a step-wise manner, for researchers who intend to validate prognostic biomarkers in PC. Combining multiple biomarkers with clinical and pathologic parameters that are predictive of outcome will aid in clinical decision-making for patients treated for PC. |
| first_indexed | 2024-12-21T22:58:24Z |
| format | Article |
| id | doaj.art-925f32af011249508d5bb084d1f7c820 |
| institution | Directory Open Access Journal |
| issn | 1471-2490 |
| language | English |
| last_indexed | 2024-12-21T22:58:24Z |
| publishDate | 2018-09-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Urology |
| spelling | doaj.art-925f32af011249508d5bb084d1f7c8202022-12-21T18:47:23ZengBMCBMC Urology1471-24902018-09-0118111010.1186/s12894-018-0392-xThe Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validationVéronique Ouellet0Armen Aprikian1Alain Bergeron2Fadi Brimo3Robert G. Bristow4Simone Chevalier5Darrel Drachenberg6Ladan Fazli7Neil E. Fleshner8Martin Gleave9Pierre Karakiewicz10Laurence Klotz11Louis Lacombe12Jean-Baptiste Lattouf13Theodorus van der Kwast14Jeremy A. Squire15Mathieu Latour16Dominique Trudel17Anne-Marie Mes-Masson18Fred Saad19Institut du cancer de Montréal and Centre de recherche du Centre hospitalier de l’Université de MontréalResearch Institute of McGill University Health Center and Department of Surgery (Urology), McGill UniversityCHU de Québec-Université Laval and Department of Surgery, Université LavalDepartment of Pathology, McGill University Health CentreDepartment of Medical Biophysics and Department of Radiation Oncology, University of TorontoResearch Institute of McGill University Health Center and Department of Surgery (Urology), McGill UniversityUniversity of Manitoba and Manitoba Prostate CentreVancouver Prostate CentreUniversity Health NetworkVancouver Prostate CentreCancer Prognostics and Health Outcomes Unit, Centre hospitalier de l’Université de MontréalSunnybrook Health Sciences CentreCHU de Québec-Université Laval and Department of Surgery, Université LavalInstitut du cancer de Montréal and Centre de recherche du Centre hospitalier de l’Université de MontréalUniversity Health NetworkDepartment of Pathology and Molecular Medicine, Queen’s UniversityInstitut du cancer de Montréal and Centre de recherche du Centre hospitalier de l’Université de MontréalInstitut du cancer de Montréal and Centre de recherche du Centre hospitalier de l’Université de MontréalInstitut du cancer de Montréal and Centre de recherche du Centre hospitalier de l’Université de MontréalInstitut du cancer de Montréal and Centre de recherche du Centre hospitalier de l’Université de MontréalAbstract Background Refinement of parameters defining prostate cancer (PC) prognosis are urgently needed to identify patients with indolent versus aggressive disease. The Canadian Prostate Cancer Biomaker Network (CPCBN) consists of researchers from four Canadian provinces to create a validation cohort to address issues dealing with PC diagnosis and management. Methods A total of 1512 radical prostatectomy (RP) specimens from five different biorepositories affiliated with teaching hospitals were selected to constitute the cohort. Tumoral and adjacent benign tissues were arrayed on tissue microarrays (TMAs). A patient clinical database was developed and includes data on diagnosis, treatment and clinical outcome. Results Mean age at diagnosis of patients in the cohort was 61 years. Of these patients, 31% had a low grade (≤6) Gleason score (GS), 55% had GS 7 (40% of 3 + 4 and 15% of 4 + 3) and 14% had high GS (≥8) PC. The median follow-up of the cohort was 113 months. A total of 34% had a biochemical relapse, 4% developed bone metastasis and 3% of patients died from PC while 9% died of other causes. Pathological review of the TMAs confirmed the presence of tumor and benign tissue cores for > 94% of patients. Immunohistochemistry and FISH analyses, performed on a small set of specimens, showed high quality results and no biorepository-specific bias. Conclusions The CPCBN RP cohort is representative of real world PC disease observed in the Canadian population. The frequency of biochemical relapse and bone metastasis as events allows for a precise assessment of the prognostic value of biomarkers. This resource is available, in a step-wise manner, for researchers who intend to validate prognostic biomarkers in PC. Combining multiple biomarkers with clinical and pathologic parameters that are predictive of outcome will aid in clinical decision-making for patients treated for PC.http://link.springer.com/article/10.1186/s12894-018-0392-xProstate cancerTissue microarrayBiomarker validationImmunohistochemistryPatient prognosis |
| spellingShingle | Véronique Ouellet Armen Aprikian Alain Bergeron Fadi Brimo Robert G. Bristow Simone Chevalier Darrel Drachenberg Ladan Fazli Neil E. Fleshner Martin Gleave Pierre Karakiewicz Laurence Klotz Louis Lacombe Jean-Baptiste Lattouf Theodorus van der Kwast Jeremy A. Squire Mathieu Latour Dominique Trudel Anne-Marie Mes-Masson Fred Saad The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation BMC Urology Prostate cancer Tissue microarray Biomarker validation Immunohistochemistry Patient prognosis |
| title | The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation |
| title_full | The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation |
| title_fullStr | The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation |
| title_full_unstemmed | The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation |
| title_short | The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation |
| title_sort | terry fox research institute canadian prostate cancer biomarker network an analysis of a pan canadian multi center cohort for biomarker validation |
| topic | Prostate cancer Tissue microarray Biomarker validation Immunohistochemistry Patient prognosis |
| url | http://link.springer.com/article/10.1186/s12894-018-0392-x |
| work_keys_str_mv | AT veroniqueouellet theterryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT armenaprikian theterryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT alainbergeron theterryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT fadibrimo theterryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT robertgbristow theterryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT simonechevalier theterryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT darreldrachenberg theterryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT ladanfazli theterryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT neilefleshner theterryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT martingleave theterryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT pierrekarakiewicz theterryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT laurenceklotz theterryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT louislacombe theterryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT jeanbaptistelattouf theterryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT theodorusvanderkwast theterryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT jeremyasquire theterryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT mathieulatour theterryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT dominiquetrudel theterryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT annemariemesmasson theterryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT fredsaad theterryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT veroniqueouellet terryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT armenaprikian terryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT alainbergeron terryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT fadibrimo terryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT robertgbristow terryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT simonechevalier terryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT darreldrachenberg terryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT ladanfazli terryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT neilefleshner terryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT martingleave terryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT pierrekarakiewicz terryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT laurenceklotz terryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT louislacombe terryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT jeanbaptistelattouf terryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT theodorusvanderkwast terryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT jeremyasquire terryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT mathieulatour terryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT dominiquetrudel terryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT annemariemesmasson terryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation AT fredsaad terryfoxresearchinstitutecanadianprostatecancerbiomarkernetworkananalysisofapancanadianmulticentercohortforbiomarkervalidation |